Intercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy.

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
• Current treatments for MN have limitations, and underlying mechanisms require further elucidation.
• Melanocortin therapy shows potential for MN, but its precise role and targets are unclear.

Purpose of the Study:

• To investigate the therapeutic potential and mechanisms of melanocortin agents in a mouse model of THSD7A-associated membranous nephropathy.
• To determine the role of melanocortin 5 receptor (MC5R) in podocytes in the context of MN pathogenesis and treatment.

Main Methods:

• Utilized a heterologous mouse model of THSD7A-associated membranous nephropathy.
• Administered various melanocortin agents, including repository corticotropin injection, NDP-MSH, and PG-901.
• Generated MC5R knockout mice and performed podocyte-specific MC5R reconstitution experiments.
• Analyzed glomerular deposition of complement components (C3, C5b-9) and expression of complement factors B and D.
• Investigated the involvement of peroxisome proliferator-activated receptor gamma (PPARγ) signaling.

Main Results:

• Melanocortin agents attenuated proteinuria and ameliorated glomerulopathy in the MN mouse model.
• MC5R knockout exacerbated MN and abolished the therapeutic effects of melanocortins.
• Podocyte MC5R was essential for melanocortin-mediated protection against MN.
• MC5R agonism reduced glomerular C5b-9 and C3 deposition by inhibiting podocyte expression of complement factors B and D via a PPARγ-dependent mechanism.

Conclusions:

• Podocyte MC5R plays a critical protective role in membranous nephropathy.
• Melanocortin therapy, through MC5R, offers a novel therapeutic strategy for MN by modulating the complement cascade.
• Targeting MC5R in podocytes may represent a new avenue for treating membranous nephropathy.